JMPWA
MRKR icon

JP Morgan Private Wealth Advisors’s Marker Therapeutics MRKR Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,750
Closed -$208K – 1493
2018
Q4 		$208K Buy
+3,750
New +$273K ﹤0.01% 1329

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Private Wealth Advisors's MRKR Position: Q1 2019 in Review

JP Morgan Private Wealth Advisors sold out of Marker Therapeutics (MRKR) in Q1 2019, closing a stake of 3,750 shares — an estimated $208K sold.

JP Morgan Private Wealth Advisors first reported a position in MRKR in Q4 2018 and held it in 1 quarter. The position peaked at $208K in Q4 2018. 56 funds tracked by Wall St. Rank hold MRKR as of Q1 2019.

  • JP Morgan Private Wealth Advisors reported no remaining Marker Therapeutics position as of Q1 2019 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 3,750 Marker Therapeutics shares in Q1 2019, an estimated $208K.
  • JP Morgan Private Wealth Advisors first reported a position in Marker Therapeutics in Q4 2018 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's Marker Therapeutics position peaked at $208K in Q4 2018.
  • 56 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2019.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q1 2019, filed 30 Apr 2019.